Back to Search
GREGORY GEBA, M.D., DR.P.H.
M.D., DR.P.H.
Internal Medicine Physician
NPI: 1639275282Individual
Specialties, Licenses & Credentials
Pulmonary Disease Physician
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
027659(CT)
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
173227(NY)
Allergy & Immunology Physician
Allergy & Immunology
Code: 207K00000X
173227(NY)
Research & Publications (20)
Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.
PMID 19671093·Pediatr Transplant·2010
3-trial
Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
PMID 19564449·Clin Pediatr (Phila)·2009
2-rct
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
PMID 19471949·Arch Dermatol Res·2009
3-trial
Treatment of chronic autoimmune urticaria with omalizumab.
PMID 18774392·J Allergy Clin Immunol·2008
3-trial
Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis.
PMID 18415822·J Asthma·2008
8-other
Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
PMID 17711616·Curr Med Res Opin·2007
3-trial
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
PMID 16484875·J Clin Rheumatol·2006
4-observational
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
PMID 15940774·J Rheumatol·2005
3-trial
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
PMID 15740544·Aliment Pharmacol Ther·2005
3-trial
Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
PMID 15556830·J Pain·2004
3-trial
Airway hyper-reactivity mediated by B-1 cell immunoglobulin M antibody generating complement C5a at 1 day post-immunization in a murine hapten model of non-atopic asthma.
PMID 15379984·Immunology·2004
7-preclinical
Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial.
PMID 15370723·Scand J Rheumatol·2004
3-trial
The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial.
PMID 15333415·Anesth Analg·2004
3-trial
Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial.
PMID 15200753·Curr Med Res Opin·2004
3-trial
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
PMID 15086644·J Am Geriatr Soc·2004
3-trial
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
PMID 14872504·Arthritis Rheum·2004
3-trial
Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.
PMID 14622687·J Pain·2003
3-trial
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
PMID 14530224·Ann Intern Med·2003
3-trial
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
PMID 12423770·FEMS Immunol Med Microbiol·2002
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 22 HOLLOWATY KOSAK ROAD
GLEN SPEY, NY 12737 - Phone
- (908) 202-5239
Quick Facts
- NPI
- 1639275282
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile